- Home
- RIGL vs CSR Comparison
RIGL vs CSR Comparison
Compare RIGL & CSR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RIGL | CSR |
|---|---|---|
| Founded | 1996 | 1970 |
| Country | United States | United States |
| Employees | N/A | 349 |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 884.9M | 931.7M |
| IPO Year | 2000 | N/A |
Fundamental Metrics
Financial Performance| Metric | RIGL | CSR |
|---|---|---|
| Price | $49.17 | $55.76 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 5 | 9 |
| Target Price | $63.00 | ★ $64.14 |
| AVG Volume (30 Days) | 194.5K | ★ 300.1K |
| Earning Date | 11-03-2026 | 11-02-2026 |
| Dividend Yield | N/A | ★ 5.61% |
| EPS Growth | ★ 1867.68 | N/A |
| EPS | ★ 1.32 | N/A |
| Revenue | ★ $294,282,000.00 | N/A |
| Revenue This Year | $3.89 | N/A |
| Revenue Next Year | $21.95 | N/A |
| P/E Ratio | ★ $36.91 | $62.27 |
| Revenue Growth | ★ 64.15 | N/A |
| 52 Week Low | $24.84 | $52.00 |
| 52 Week High | $52.24 | $69.61 |
Technical Indicators
Market Signals| Indicator | RIGL | CSR |
|---|---|---|
| Relative Strength Index (RSI) | 59.28 | 54.43 |
| Support Level | $33.93 | $54.01 |
| Resistance Level | $49.50 | $57.76 |
| Average True Range (ATR) | 1.86 | 0.99 |
| MACD | -0.07 | -0.02 |
| Stochastic Oscillator | 74.01 | 83.52 |
Price Performance
Historical ComparisonAbout RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
About CSR D/B/A Centerspace
Centerspace is a real estate investment trust (REIT) that focuses on the ownership, management, acquisitions, redevelopment, and development of apartment communities. The company operates through a single reportable segment which includes the ownership, management, development, redevelopment, and acquisition of apartment communities and conduct their corporate operations from offices in Minot, North Dakota and Minneapolis, Minnesota.